



e-therapeutics plc

("e-therapeutics" or the "Company")

Appointment of Chief Financial Officer

Oxford, UK, 29 March 2021 – e-therapeutics plc (AIM: ETX.L) today announces the appointment of Dr Karl Keegan as Chief Financial Officer ("CFO") effective immediately. The CFO role will be a non-board position.

Dr Keegan brings a depth of capital market and strategic financing experience with over 20 years' experience in the pharmaceutical and biotech industries. After working in academia and large pharma, Karl became a highly rated sell-side analyst at a number of investment banks. Since 2009, he has held senior executive roles in private and public companies, most recently as Chief Executive Officer of privately held Hox Therapeutics Limited.

Karl received his BSc in Pharmacology from University College Dublin, MPhil and PhD degrees from the University of Cambridge and his MSc (Finance) from London Business School.

Dr Keegan, Chief Financial Officer, said: "I am delighted to be joining the e-therapeutics team at such a pivotal time for the Company. The Company has built an impressive computational biology drug discovery platform and clinically validated RNA interference drug modality."

Ali Mortazavi, Chief Executive Officer, commented: "We are delighted to welcome Karl to e-therapeutics at this point in the Company's evolution. The combination of his industry and financial sector expertise will be a major addition to the team."

For further information, please contact:

e-therapeutics plc

Ali Mortazavi, CEO Tel: +44 (0)1993 883 125

www.etherapeutics.co.uk

SP Angel Corporate Finance LLP

Nominated Adviser and Broker

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Corporate Broking)

Tel: +44 (0) 20 3470 0470

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine

learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

e-therapeutics has developed an *in silico* laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.